» Articles » PMID: 18251131

The Efficacy of Terlipressin in Comparison with Albumin in the Prevention of Circulatory Changes After the Paracentesis of Tense Ascites--a Randomized Multicentric Study

Overview
Specialty Gastroenterology
Date 2008 Feb 7
PMID 18251131
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Postparacentesis circulatory dysfunction is the most severe complication of ascites paracentesis. The aim of our study was to compare the standard treatment with the administration of a vasoconstrictor terlipressin.

Methodology: Forty-nine patients treated by paracentesis due to tense ascites were randomized for the treatment with albumin (8g/L of removed ascites) or terlipressin (1 mg every four hours for 48 hours). The blood pressure, heart rate, diuresis, electrocardiograph, standard biochemical and hematological parameters, sodium, potassium and nitrogen urinary excretion, aldosterone and renin activity in the blood plasma were monitored for a period of 72 hours.

Results: In any parameter of hemodynamic changes, no statistically significant difference was demonstrated between randomized groups, in particular measurements as well as in the development in the course of the first three days after the intervention. The result suggests similar efficacy of the circulatory dysfunction prevention after the paracentesis in both treatment procedures. In both groups, on the first three days, there was a tendency to improve hemodynamics reflected by the renin-angiotensin-aldosteron system activity. In the terlipressin group, this tendency approached statistically significant levels.

Conclusions: The administration of terlipressin in a dose of 1 mg every fourth hour performed for a period of 48 hours was as effective as intravenous albumin in preventing hemodynamic changes in patients with tense ascites treated by paracentesis. The treatment was well tolerated.

Citing Articles

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.

Bai Z, An Y, Guo X, Teschke R, Mendez-Sanchez N, Li H Can J Gastroenterol Hepatol. 2020; 2020:5106958.

PMID: 32676484 PMC: 7333040. DOI: 10.1155/2020/5106958.


Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Benmassaoud A, Freeman S, Roccarina D, Torres M, Sutton A, Cooper N Cochrane Database Syst Rev. 2020; 1:CD013123.

PMID: 31978257 PMC: 6984622. DOI: 10.1002/14651858.CD013123.pub2.


KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Clin Mol Hepatol. 2018; 24(3):230-277.

PMID: 29991196 PMC: 6166105. DOI: 10.3350/cmh.2018.1005.


The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.

Elsabaawy M, Abdelhamid S, Alsebaey A, Abdelsamee E, Obada M, Salman T Clin Mol Hepatol. 2016; 21(4):365-71.

PMID: 26770925 PMC: 4712164. DOI: 10.3350/cmh.2015.21.4.365.


The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.

Bari K, Minano C, Shea M, Inayat I, Hashem H, Gilles H Clin Gastroenterol Hepatol. 2012; 10(10):1169-75.

PMID: 22801062 PMC: 3678262. DOI: 10.1016/j.cgh.2012.06.027.